Medications for Cytomegalovirus Infections

6 results

  • Ganciclovir (ganciclovir sodium)

    (ganciclovir sodium)
    Hainan Poly Pharm. Co., Ltd.
    Usage: Ganciclovir for Injection is indicated for the treatment of cytomegalovirus (CMV) retinitis in immunocompromised adults, including those with AIDS, and for the prevention of CMV disease in adult transplant recipients at risk for this condition.

  • Ganciclovir sodium (ganciclovir sodium)

    (ganciclovir sodium)
    Slate Run Pharmaceuticals, LLC
    Usage: Ganciclovir for Injection is indicated for treating cytomegalovirus (CMV) retinitis in immunocompromised adults, including those with AIDS, and for preventing CMV disease in at-risk adult transplant recipients.

  • Livtencity

    (MARIBAVIR)
    Takeda Pharmaceuticals America, Inc.
    Usage: LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years and older, weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet.

  • Prevymis

    (LETERMOVIR)
    Merck Sharp & Dohme LLC
    Usage: PREVYMIS® is indicated for the prophylaxis of cytomegalovirus (CMV) infection in adult and pediatric patients. It is used for CMV prevention in hematopoietic stem cell transplant recipients aged 6 months and older and in high-risk kidney transplant recipients aged 12 years and older.

  • Valcyte (valganciclovir)

    (valganciclovir)
    Genentech, Inc.
    Usage: VALCYTE is indicated for the treatment of cytomegalovirus (CMV) retinitis in adults with AIDS. It also prevents CMV disease in high-risk transplant patients: kidney, heart, and kidney-pancreas recipients, as well as pediatric kidney and heart transplant patients aged 1 month to 16 years.

  • Valganciclovir hydrochloride (valganciclovir hydrochloride)

    (Valganciclovir hydrochloride)
    Ajanta Pharma USA Inc.
    Usage: Valganciclovir is indicated for treating cytomegalovirus (CMV) retinitis in AIDS patients and for preventing CMV disease in high-risk transplant recipients (adults and pediatric patients) including kidney and heart transplants.